HIV Latency and Nanomedicine Strategies for Anti-HIV Treatment and Eradication

Antiretrovirals (ARVs) reduce Human Immunodeficiency Virus (HIV) loads to undetectable levels in infected patients. However, HIV can persist throughout the body in cellular reservoirs partly due to the inability of some ARVs to cross anatomical barriers and the capacity of HIV-1 to establish latent infection in resting CD4+ T cells and monocytes/macrophages. A cure for HIV is not likely unless latency is addressed and delivery of ARVs to cellular reservoir sites is improved. Nanomedicine has been used in ARV formulations to improve delivery and efficacy. More specifically, researchers are exploring the benefit of using nanoparticles to improve ARVs and nanomedicine in HIV eradication strategies such as shock and kill, block and lock, and others. This review will focus on mechanisms of HIV-1 latency and nanomedicine-based approaches to treat HIV.

Automated summary

Antiretrovirals (ARVs) can reduce Human Immunodeficiency Virus (HIV) loads to undetectable levels in infected patients. However, HIV can persist in cellular reservoirs due to certain ARVs' inability to cross anatomical barriers and HIV-1's ability to establish latent infection. Nanomedicine has been used to improve ARV delivery and efficacy in HIV eradication strategies. This review focuses on HIV-1 latency mechanisms and nanomedicine-based approaches for treating HIV.